Investigation Report on China Moxifloxacin Industry 2010-2019
As the fourth generation of quinolones drugs, moxifloxacin (moxifloxacin hodrochloride) was first introduced to the market by The Bayer Group in Sep. 1999. It is utilized in the treatment of adult patients (aged 18 and above) diagnosed with upper and lower respiratory tract infections, e.g. acute sinusitis, acute exacerbation of chronic bronchitis (AECB), community-acquired pneumonia, and skin and soft issue infection.
View full press release